WO2016077884A1 - Composition topique - Google Patents

Composition topique Download PDF

Info

Publication number
WO2016077884A1
WO2016077884A1 PCT/AU2015/050726 AU2015050726W WO2016077884A1 WO 2016077884 A1 WO2016077884 A1 WO 2016077884A1 AU 2015050726 W AU2015050726 W AU 2015050726W WO 2016077884 A1 WO2016077884 A1 WO 2016077884A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
caffeine
skin
dermatologically
water content
Prior art date
Application number
PCT/AU2015/050726
Other languages
English (en)
Inventor
Stephen Rowley
Alex BOFFA
Original Assignee
Sndr Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014904626A external-priority patent/AU2014904626A0/en
Application filed by Sndr Pty Ltd filed Critical Sndr Pty Ltd
Publication of WO2016077884A1 publication Critical patent/WO2016077884A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to topical compositions for application to the skin of humans and other animals, and to their use in improving the condition and appearance of skin.
  • the present compositions may also be used in therapeutic indications for the skin, and also tissues beneath the upper layers of the skin such as the subdermis. BACKGROUND TO THE INVENTION
  • compositions for the treatment of skin conditions There is a constant need for improved or alternative compositions for the treatment of skin conditions.
  • the cosmetic market for example, is replete with topical compositions directed to the treatment of aesthetic conditions such as cellulite, wrinkles, skin laxity, skin discolouration, blemishes, pimples, flaking skin, dry skin, and the like.
  • compositions also claim efficacy in the treatment of conditions which are metabolic in nature such as excess adipose tissue about the skin, fluid retention, toxin deposition and the like. Such problems may also present an aesthetic issue (such as cellulite).
  • the prior art further teaches the addition of biologically active ingredients such as minerals, vitamins (such as A and C), vitamin derivatives (such as retinoids), amino acids, coenzymes, peptides, larger proteins (such as collagen), polysaccharides, alkaloids and the like to base compositions.
  • biologically active ingredients such as minerals, vitamins (such as A and C), vitamin derivatives (such as retinoids), amino acids, coenzymes, peptides, larger proteins (such as collagen), polysaccharides, alkaloids and the like to base compositions.
  • the active ingredient crosses the horny epidermis and into the dermis (or even into the subdermis) to exert a functional effect on viable cells of the skin.
  • an active To be properly absorbed through the skin, an active must pass through the stratum corneum, which is the outermost layer of the epidermis and the rate-limiting barrier in absorption of a many actives.
  • any particular active is capable of crossing the significant barrier formed by the stratum corneum, and indeed even underlying structures such as the stratum germinativum, and adipose layers. Accordingly, many different formulations have been provided for any given active in order improve transport of the active across the skin. For example, penetration of vitamin C is thought to be minimal without the addition of a divalent cation (such as Zinc) in combination with a phenyl-based amino acid (such as tyrosine).
  • a divalent cation such as Zinc
  • a phenyl-based amino acid such as tyrosine
  • Caffeine is an active ingredient that has been utilized in a range of topical formulations. It is thought that the topical application of caffeine may provide a number of aesthetic or therapeutic outcomes for a user. For example, caffeine is known to reduce blood flow by mild constriction of blood vessels. Caffeine has also demonstrated antioxidant and antiinflammatory activities which assist in the treatment of skin conditions. In vitro metabolism studies on fat cells have shown that caffeine may decrease the rate of lipogenesis while stimulating the lipolysis via the inhibition of phosphoesterase.
  • caffeine is thought to have some ability to improve certain conditions of the skin or subdermis, there has been little study of the ability for caffeine to enter the skin to exert any biological effect. Some studies have shown that the sweat glands are an important portal of entry, while others show absorption via the hair follicles. A number of trials of topical caffeine containing skin compositions have shown disappointing results, and the possibility remains that less than optimal amounts of caffeine are deliverable to the dermis and subdermis.
  • compositions useful in dermatological applications.
  • the composition may provide for an improved rate or extent of delivery of caffeine to tissues of the skin.
  • the composition may provide for ease of application of caffeine, or a more acceptable appearance or feel to the skin after application.
  • present compositions may be simply an alternative to topical caffeine compositions of the prior art.
  • the present invention provides a topical composition for use on the skin of an animal, the composition comprising caffeine in combination with one or more dermatologically-acceptable or pharmaceutically acceptable excipients, wherein the composition has a relatively low water content.
  • the water content is less than about 10% (wt/wt), or less than about 1 % (wt/wt), or is trace, or is substantially 0% (wt/wt).
  • the caffeine is an extract from a plant of the genus Coffea or Camellia.
  • the caffeine is present in the form of a seed oil. In one embodiment, the caffeine containing extract is present in an amount of up to about 10% (wt/wt), or up to about 1 % (wt/wt), or up to about 0.1 % (wt/wt).
  • the dermatologically acceptable excipient(s) and/or pharmaceutically acceptable excipients is/are substantially non-polar and/or hydrophobic and/or lipophilic, or are predominantly substantially non-polar and/or hydrophobic and/or lipophilic.
  • the dermatologically-acceptable excipient(s) and/or pharmaceutically acceptable excipients is/are plant-derived.
  • the dermatologically-acceptable excipient(s) and/or pharmaceutically acceptable excipients is/are extracted from a plant seed.
  • the present invention provides a method of producing a topical composition for use on the skin of an animal, the method comprising the steps of: providing a caffeine-containing extract from a tissue of a plant, and combining the caffeine containing extract with a dermatologically or pharmaceutically acceptable excipient.
  • the present invention provides a method of treating or preventing a condition relating to the epidermis, dermis or subdermis, the method comprising the steps of: providing the composition as described herein, and contacting the composition with the epidermis of animal in need thereof with a dermatologically or therapeutically effective amount of the composition under conditions allowing for the transport of the caffeine present in the caffeine-containing extract into or across the epidermis.
  • condition relating to the epidermis, dermis or subdermis relates to the function of an adipocyte and/or a fibroblast.
  • condition relating to the epidermis, dermis or subdermis selected from the group consisting of cellulite, excess adipose tissue, a rhytide, cutis laxa, thin skin, discoloured skin, dry skin, abnormal or impaired vascularity, the presence of a toxin, skin swelling, and lyphodema.
  • the present invention is predicated at least in part on Applicant's finding that decreasing water content in topical caffeine formulations provides aesthetic and functional improvements in the skin, and also tissues beneath the skin. Accordingly, in a first aspect, the present invention provides a topical composition for use on the skin of an animal, the composition comprising caffeine in combination with one or more dermatologically- acceptable or pharmaceutically acceptable excipients, wherein the composition has a relatively low water content. It has been found that caffeine containing topical compositions are preferred by consumers where the water content of the composition is relatively low.
  • the term "animal” is intended to include without limitation any mammal such as a human, primate, domestic animal, beast of burden, zoo animal, agriculturally or economically significant animal.
  • any mammal such as a human, primate, domestic animal, beast of burden, zoo animal, agriculturally or economically significant animal.
  • the term "dermatologically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier, including those approved by the United States Food and Drug Administration as being acceptable for dermatological use on humans, or which are known, or are suitable for use in dermatological compositions.
  • the term "pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration.
  • the term "low" with respect to water content is intended to mean that the composition has a water content which is lower than oil-in-water or water-in-oil emulsions which are well know bases in the cosmetics formulation arts.
  • skin lotions of the prior art may have a water content of up to about 90%, with the remainder of the composition including ingredients such as oils, emulsifiers, fragrances, preservatives, actives and the like.
  • the present invention is a significant departure from prior art lotions by providing caffeine in a low water topical composition.
  • Applicant has recognised a problem with prior art compositions in that caffeine is only sparingly soluble in water at ambient temperature, and so tends to precipitate out of relatively high water content compositions such as lotions and creams. It has been found that precipitation of caffeine may be reduced (or even avoided) where the water content of a caffeine-containing compositions is decreased. Thus, even a slight decrease in water content will result in a low propensity for caffeine to precipitate out of the composition.
  • Water content may be reduced by formulating the composition using an anhydrous form of caffeine.
  • caffeine may be isolated by water extraction methods whereby coffee beans are first soaked in water. The water is then passed through activated charcoal, which adsorbs the caffeine. The caffeine is reclaimed from the charcoal and dried to provide a substantially anhydrous form of caffeine.
  • Another method is by supercritical carbon dioxide extraction whereby carbon dioxide is forced through coffee beans at temperatures above 31 .1 °C and pressures above 73 atm. Under these conditions, carbon dioxide is in a "supercritical" state, and capable of dissolving 97-99% of the caffeine.
  • the caffeine-laden gas is then sprayed with high pressure water to remove the caffeine.
  • the caffeine can then be further isolated by charcoal adsorption (as above) or by distillation, recrystallization, or reverse osmosis.
  • a further method is by extraction using organic solvents such as ethyl acetate or dichloromethane.
  • organic solvents such as ethyl acetate or dichloromethane.
  • the extracted caffeine is then dried to a powdered form.
  • the caffeine of the topical composition is used in the form of a caffeine- containing oil obtained from a tissue of a plant (such as a plant of the genus Coffea or Camellia).
  • a tissue of a plant such as a plant of the genus Coffea or Camellia
  • triglyceride oils may be obtained from coffee beans (for example by cold pressing) with these oils being rich in caffeine.
  • An advantage of this embodiment of the composition is that the caffeine is used in a naturally occurring form, having not been exposed to solvents or any other artificial compound or process.
  • the caffeine is present amongst a matrix of non-caffeine compounds some of which are biologically active.
  • chlorogenic acid found in green coffee
  • Other actives include diterpenes, such as cafestol and kahweol which are thought to have anticarcinogenic properties.
  • the topical composition may have a water content of less than about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 25%, 20%, 15%, 10%, or 5% (wt/wt).
  • caffeine preparations having some water content may be used as the source of caffeine for the present compositions.
  • water extracted caffeine which is still in aqueous solution may be used so long as the total water content of the composition is lower than that of a prior art lotion or cream.
  • water within which the caffeine is dissolved (and added to form the composition) contributes toward the total water content of the topical composition.
  • the water content of any non-caffeine substantially aqueous component contributes toward the total water content of the topical composition.
  • the topical composition has a water content which is low (in an absolute sense) and may be less than about 5%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1 .5%, 1 .0%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1 % (wt/wt).
  • the composition is substantially free of water (i.e. about 0% (wt/wt)).
  • the caffeine is delivered to the skin in a substantially non-aqueous (or substantially oily) vehicle.
  • the caffeine is carried in a substantially lipophilic vehicle and therefore has a greater propensity to cross the stratum corneum (at least) and therefore contact the viable underlying cells of the dermis and/or subdermis.
  • the composition remains for a longer period on the skin surface (or within the stratum corneum) given the lower amounts of water (which may be considered a volatile solvent in prior art lotions and creams).
  • the longer residence time in or on the skin may provide a depot effect whereby caffeine enters the underlying tissues over a period of time, this avoiding a sharp peaking caffeine dosage being provided shortly after application.
  • the composition provides an improved immediate cosmetic effect for the user's skin. Higher oil content compositions may provide an aesthetically desirable shine or a glow to the skin surface.
  • composition is more easily applied, or in more pleasurable to apply to the skin.
  • the caffeine in the present compositions may be present as a trace amount or even up to saturation amounts.
  • the amount may vary according to the condition to be treated, a proposed dosage regime, the species of animal to be treated, the physiological state of the animal to be treated, and any other matter deemed pertinent by the skilled person.
  • the caffeine is present in the composition in an amount of up to about 10%. 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1 %, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.3% or 0.1 %.
  • the composition comprises non-caffeine containing oils, and particularly plant-derived oils.
  • oils derived from grape seed, almond, orange peel oil, hemp seed oil, coconut oil, cocoa seed oil, and the like may separately, or in any combination, be useful in the present compositions.
  • the topical composition is formulated as a body balm or butter, and may therefore comprise one or more oils, waxes, butters, fats and the like known to be useful in the manufacture of such products. Otherwise, the compositions may be formulated more so according to a lotion or a cream, although in any event having a lower water content than any prior art lotion or cream. As required, and with the benefit of the present specification the skilled person is enabled to decide whether or not any buffer or salt is required to provide a required pH of ionic strength for the composition. Acceptable salts include those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid.
  • Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
  • Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • basic ion exchange resins such as ammonia, is
  • the present invention provides a method of producing a topical composition for use on the skin of an animal, the method comprising the steps of: providing caffeine, and combining the caffeine containing extract with a dermatologically or pharmaceutically acceptable excipient.
  • a dermatologically or pharmaceutically acceptable excipient Where an ingredient is solid (or at least very viscous) at ambient temperature, that ingredient (either alone or when already in a mixture) may be heated to improve the ability to combine with, mix with, or solubilise other components of the composition.
  • the composition may be dispensed into a container to form a vendible product before complete cooling and solidification of any component.
  • the present invention provides a method of treating or preventing a condition relating to the epidermis, dermis or subdermis, the method comprising the steps of: providing the composition as described herein, and contacting the composition with the epidermis of animal in need thereof with a dermatologically or therapeutically effective amount of the composition under conditions allowing for the transport of the caffeine present in the caffeine-containing extract into or across the epidermis.
  • Treating covers the treatment of the disorder or condition of interest in a human having the disorder or condition of interest, and includes:
  • Dermatologically effective amount refers to that amount of an active ingredient which, when administered dermatologically (i.e., topically) to an animal, is sufficient to effect the desired treatment, as defined below, of the condition of interest in the animal.
  • the amount of an active ingredient which constitutes a “dermatologically effective amount” may vary depending on, the condition and its severity, and the age of the animal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • “Therapeutically effective amount” refers to that amount of an active ingredient which, when administered orally to an animal, is sufficient to effect the desired treatment, as defined below, of the condition of interest in the animal.
  • the amount of an active ingredient which constitutes a “therapeutically effective amount” may vary depending on, the condition and its severity, and the age of the animal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • the condition relating to the epidermis, dermis or subdermis may be selected from the group consisting of cellulite, excess adipose tissue, a rhytide, cutis laxa, thin skin, discoloured skin, dry skin, abnormal or impaired vascularity, the presence of a toxin, skin swelling, and lyphodema.
  • Caffeine has known biological activities with respect to a range of cell types. With reference to the present invention such biological activities may be directed against any cell of the epidermis, dermis or subdermis such as an adipocyte and/or a fibroblast.
  • the composition is typically self-applied by the user, by placing an aliquot on the hand and smoothing the composition of the skin requiring treatment.
  • the oil was cold pressed and used as an essential oil without further modification.
  • Roasted Coffea arabica beans were used for all pressings.
  • Preferred Composition 1. Substantially water-free body balm
  • Preferred Composition 3 Low water content composition with emulsifying agent - second embodiment
  • Cocos Nucifera (Coconut) Oil 10.0 8001 -31 -8 coconut Oil
  • Preferred Composition Substantially water-free body balm using anhydrous caffeine.
  • Cocos Nucifera (Coconut) Oil 10.0 8001 -31 -8 coconut Oil
  • Vitis Vinifera Fruit 0.001 84929-27-1 Grape Fruit Seed Extract Extract
  • Preferred Composition 1 as detailed supra was used in a prospective cohort study of 10 women between the ages of 18 and 25 years. All participants demonstrated physical signs of cellulite on the thighs and buttocks.
  • composition A liberal amount of the composition was self-applied daily to the thighs and buttocks (typically after bathing) for a period of 4 weeks. All participants reported the composition was easy to apply and, and agreed with the proposition that the composition left an aesthetically pleasing shine to the skin.
  • Preferred Composition 5 as detailed supra was used in a prospective cohort study of 12 women between the ages of 45 and 55 years. All participants demonstrated physical signs of skin laxity about the abdomen.
  • composition A liberal amount of the composition was self-applied daily to the abdomen (typically after bathing) for a period of 4 weeks. All participants reported the composition was easy to apply and, and agreed with the proposition that the composition left an aesthetically pleasing shine to the skin.
  • Preferred Composition 6 as detailed supra was used in a prospective cohort study of 25 women between the ages of 35 and 45 years. All participants demonstrated at least one physical sign of ageing about the face and neck including skin pigmentation/discolouration, skin laxity, redness/inflammation, dry skin, and wrinkles. A sparing amount of the composition was self-applied daily to the face and neck (typically before bed time) for a period of 12 weeks. All participants reported the composition was easy to apply and, and agreed with the proposition that the composition left an aesthetically pleasing shine to the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition topique pour utilisation sur la peau d'un animal, la composition comprenant de la caféine en combinaison avec un ou plusieurs excipients dermatologiquement acceptables ou pharmaceutiquement acceptables, la composition ayant une teneur relativement faible en eau. Des teneurs en eau inférieures à 10 % ou inférieures à 1 %, ou des traces d'eau, sont envisagées. Les compositions peuvent être utilisées pour traiter un état pathologique associé à l'épiderme, au derme et à l'hypoderme, comme la cellulite, la cutis laxa, la peau sèche et le lymphœdème.
PCT/AU2015/050726 2014-11-18 2015-11-18 Composition topique WO2016077884A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014904626A AU2014904626A0 (en) 2014-11-18 Topical composition
AU2014904626 2014-11-18

Publications (1)

Publication Number Publication Date
WO2016077884A1 true WO2016077884A1 (fr) 2016-05-26

Family

ID=56012964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2015/050726 WO2016077884A1 (fr) 2014-11-18 2015-11-18 Composition topique

Country Status (1)

Country Link
WO (1) WO2016077884A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183630A1 (fr) * 2015-05-19 2016-11-24 Sndr Pty Ltd Composition hydratante pour la peau
WO2016183634A1 (fr) * 2015-05-19 2016-11-24 Sndr Pty Ltd Composition exfoliante pour la peau

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344188B1 (en) * 2000-03-01 2002-02-05 Victor Silva, Inc. Wrinkle reducing cream
EP1566169A1 (fr) * 2004-02-10 2005-08-24 ABOCA S.p.A. Compositions cosmétiques contenant des extraits d'espèces de Bupleurum et des extraits de Salvia miltiorrhiza pour le traitement et le reduction des tâches causées par la cellulite.
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20090291051A1 (en) * 2008-04-25 2009-11-26 L'oreal Compositions having a heating effect
US20110033399A1 (en) * 2009-08-04 2011-02-10 Gardner Margaret M Therapeutic vitamin d sun-protecting formulations and methods for their use
WO2011156803A2 (fr) * 2010-06-11 2011-12-15 Transdel Pharmaceuticals, Inc. Composition anticellulite et procédé de traitement de la cellulite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344188B1 (en) * 2000-03-01 2002-02-05 Victor Silva, Inc. Wrinkle reducing cream
EP1566169A1 (fr) * 2004-02-10 2005-08-24 ABOCA S.p.A. Compositions cosmétiques contenant des extraits d'espèces de Bupleurum et des extraits de Salvia miltiorrhiza pour le traitement et le reduction des tâches causées par la cellulite.
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20090291051A1 (en) * 2008-04-25 2009-11-26 L'oreal Compositions having a heating effect
US20110033399A1 (en) * 2009-08-04 2011-02-10 Gardner Margaret M Therapeutic vitamin d sun-protecting formulations and methods for their use
WO2011156803A2 (fr) * 2010-06-11 2011-12-15 Transdel Pharmaceuticals, Inc. Composition anticellulite et procédé de traitement de la cellulite

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183630A1 (fr) * 2015-05-19 2016-11-24 Sndr Pty Ltd Composition hydratante pour la peau
WO2016183634A1 (fr) * 2015-05-19 2016-11-24 Sndr Pty Ltd Composition exfoliante pour la peau

Similar Documents

Publication Publication Date Title
CA2570210C (fr) Compositions comprenant des extraits de centella asiatica et de cafe vert favorisant la pousse des cheveux
AU2011325867B2 (en) Methods and compositions for maintaining and improving the health of skin
CA2485403C (fr) Utilisation de pourpier pour le traitement de rides du visage
WO2008139182A2 (fr) Composition pour le soin de la peau
US20060263400A1 (en) Regulation of mammalian keratinous tissue using skin and/or hair care actives
JP2001504463A (ja) ククイノキナッツ油を含有する医薬組成物
CN111372595A (zh) 治疗皮肤的方法和组合物
US8986755B1 (en) Skin moisturizer
KR20160120355A (ko) 피부-윤광 화장품 조성물
US9956163B2 (en) Formulations for lightening skin and treating hyperpigmentation
WO2016077884A1 (fr) Composition topique
US8124141B2 (en) Rapidly absorbing lipophilic skin compositions and uses therefor
US8003142B2 (en) Therapeutic and cosmetic balsam
KR101661694B1 (ko) 히드로퀴논을 포함하는 저자극성 피부 미백용 조성물
Shah et al. Integrative approaches to hyperpigmentation therapy
WO2009020398A2 (fr) Produit de soins de la peau
JPH11199444A (ja) 白髪の予防・治療剤
RU2308962C1 (ru) Средство для лечения и профилактики заболеваний опорно-двигательного аппарата
CN111544350A (zh) 一种净颜祛痘精华液
UA23302U (en) Cream for feet and shin skin care
WO2016183630A1 (fr) Composition hydratante pour la peau
JP2013538866A (ja) 皮膚治療のための組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15861639

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15861639

Country of ref document: EP

Kind code of ref document: A1